Hot Pursuit     17-Mar-25
Zydus Life gains as Gujarat facility clears USFDA inspection with zero observations
Zydus Lifesciences rose 1.67% to Rs 897.25 after the firm said that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the company’s Active Pharmaceutical Ingredient (API) Unit 1, located in Ankleshwar, Gujarat.

The said inspection was conducted from 10 March to 14 March 2025 and concluded with zero observations from the regulatory body.

The official announcement was made on 14 March 2025.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Previous News
  Zydus Lifesciences consolidated net profit rises 30.64% in the June 2024 quarter
 ( Results - Announcements 09-Aug-24   13:48 )
  Market opens on firm note; breadth strong
 ( Market Commentary - Mid-Session 26-Aug-24   09:35 )
  Zydus receives USFDA approval for Jaythari® (Deflazacort) Tablets
 ( Corporate News - 12-Apr-25   13:35 )
  Zydus Life gains as Gujarat facility clears USFDA inspection with zero observations
 ( Hot Pursuit - 17-Mar-25   09:49 )
  Zydus' Ankleshwar unit successfully completes USFDA inspection
 ( Corporate News - 15-Mar-25   11:27 )
  Indices trade with moderate losses; PSU bank shares decline
 ( Market Commentary - Mid-Session 23-Jul-24   14:31 )
  Board of Zydus Lifesciences recommends Final Dividend
 ( Corporate News - 17-May-24   16:18 )
  Zydus Life’s Gujarat facility clears USFDA inspection with zero observations
 ( Hot Pursuit - 15-Mar-25   10:19 )
  Zydus Life rises after USFDA grants orphan drug status to Usnoflast for ALS treatment
 ( Hot Pursuit - 23-Jan-25   12:04 )
  Volumes spurt at Zydus Lifesciences Ltd counter
 ( Hot Pursuit - 07-Jan-25   11:00 )
  Zydus Lifesciences API unit in Ambernath clears USFDA inspection
 ( Corporate News - 14-Feb-25   19:18 )
Other Stories
  Kamat Hotels Q4 PAT surges 412% YoY to Rs 11 cr
  26-Apr-25   16:21
  Bank of Maharashtra Q4 PAT climbs 23% YoY to Rs 1,493 crore
  26-Apr-25   15:34
  Oracle Financial Services Software Q4 PAT up 19% QoQ
  26-Apr-25   14:28
  Force Motors Q4 PAT surges 210% YoY to Rs 435 cr; declares dividend of Rs 40/sh
  26-Apr-25   14:02
  L&T Finance Q4 PAT rises 15% YoY to Rs 636 crore
  26-Apr-25   13:31
  RBL Bank PAT drops 81% YoY to Rs 69 crore in Q4 FY25; provisions zoom by 90% YoY
  26-Apr-25   12:12
  Tejas Networks reports dismal Q4 outcome
  26-Apr-25   11:54
  Zydus Life gets 6 observations from USFDA for API plant
  26-Apr-25   11:02
  RIL Q4 PAT rises 6.4% YoY
  26-Apr-25   10:05
  Tata Technologies Q4 PAT climbs 12% QoQ to Rs 189 cr
  25-Apr-25   17:34
Back Top